Debiopharm has bought a phase 2 antibody-drug conjugate (ADC) from ImmunoGen to add to its clinical-phase cancer pipeline.

VitalConnect raised $33 million in series C funding to boost the commercialization of its disposable adhesive patient-monitoring sensor.

TP Therapeutics has the funds on hand to take its drug for resistant cancer through the next stages of clinical development after raising $45 million in a…

Bioverativ has struck a deal to buy rare disease biotech True North Therapeutics.

President Donald Trump’s administration has released a breakdown of its attempts to cut back on healthcare and research spending across the government, with…

Shares in Puma Biotechnology jumped 40% after the FDA trod lightly around doubts about its filing for approval of breast cancer drug neratinib.

ViaCyte picked up $10 million to fund the clinical development of its stem cell-derived treatment for patients who have Type 1 diabetes and are at risk of…

Perennial biotech investor and backer Takeda has signed its latest collaboration with Nektar Therapeutics that will see the pair work on combo cancer…

Amgen and UCB's romosozumab trounced a comparator drug in a trial in osteoporosis, but there's a big catch: The therapy seems to cause side effects…